Finch Therapeutics Group Stock Performance
| FNCH Stock | USD 12.75 0.55 4.14% |
The firm shows a Beta (market volatility) of 0.0301, which means not very significant fluctuations relative to the market. As returns on the market increase, Finch Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Finch Therapeutics is expected to be smaller as well. At this point, Finch Therapeutics has a negative expected return of -0.0995%. Please make sure to confirm Finch Therapeutics' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Finch Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Finch Therapeutics Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental indicators, Finch Therapeutics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Finch |
Finch Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,365 in Finch Therapeutics Group on November 21, 2025 and sell it today you would lose (90.00) from holding Finch Therapeutics Group or give up 6.59% of portfolio value over 90 days. Finch Therapeutics Group is currently does not generate positive expected returns and assumes 1.7994% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of pink sheets are less volatile than Finch, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Finch Therapeutics Target Price Odds to finish over Current Price
The tendency of Finch Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.75 | 90 days | 12.75 | close to 99 |
Based on a normal probability distribution, the odds of Finch Therapeutics to move above the current price in 90 days from now is close to 99 (This Finch Therapeutics Group probability density function shows the probability of Finch Pink Sheet to fall within a particular range of prices over 90 days) .
Finch Therapeutics Price Density |
| Price |
Predictive Modules for Finch Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Finch Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Finch Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Finch Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Finch Therapeutics is not an exception. The market had few large corrections towards the Finch Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Finch Therapeutics Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Finch Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.35 | |
Ir | Information ratio | -0.1 |
Finch Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Finch Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Finch Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Finch Therapeutics generated a negative expected return over the last 90 days | |
| Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
| Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: Biotricity GAAP EPS of -0.04, revenue of 4M |
Finch Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Finch Pink Sheet often depends not only on the future outlook of the current and potential Finch Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Finch Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.6 M | |
| Cash And Short Term Investments | 25.1 M |
Finch Therapeutics Fundamentals Growth
Finch Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Finch Therapeutics, and Finch Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Finch Pink Sheet performance.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.22 | |||
| Current Valuation | 10.74 M | |||
| Shares Outstanding | 1.61 M | |||
| Price To Book | 0.14 X | |||
| Price To Sales | 30.46 X | |||
| Revenue | 107 K | |||
| EBITDA | (32.48 M) | |||
| Cash And Equivalents | 104.67 M | |||
| Cash Per Share | 2.19 X | |||
| Total Debt | 30.13 M | |||
| Debt To Equity | 0.35 % | |||
| Book Value Per Share | 11.86 X | |||
| Cash Flow From Operations | (31.5 M) | |||
| Earnings Per Share | (6.59) X | |||
| Total Asset | 71 M | |||
| Retained Earnings | (350.39 M) | |||
About Finch Therapeutics Performance
By evaluating Finch Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Finch Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Finch Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Finch Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.Things to note about Finch Therapeutics performance evaluation
Checking the ongoing alerts about Finch Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Finch Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Finch Therapeutics generated a negative expected return over the last 90 days | |
| Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
| Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: Biotricity GAAP EPS of -0.04, revenue of 4M |
- Analyzing Finch Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Finch Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Finch Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Finch Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Finch Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Finch Therapeutics' pink sheet. These opinions can provide insight into Finch Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Finch Pink Sheet analysis
When running Finch Therapeutics' price analysis, check to measure Finch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Finch Therapeutics is operating at the current time. Most of Finch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Finch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Finch Therapeutics' price. Additionally, you may evaluate how the addition of Finch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |